Showing results (21-30 of 92) with videos related to
Sort By:
Pageof 10
Diabetes|August 22, 2015
Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse ModelsStanley Lasch, Peter Müller, Monika Bayer, et al.Cell Adhesion & Migration|April 26, 2016
Murine junctional adhesion molecules JAM-B and JAM-C mediate endothelial and stellate cell interactions during hepatic fibrosisEdith Hintermann, Monika Bayer, Janine Ehser, et al.Journal of Autoimmunity|December 4, 2012
Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitisJanine Ehser, Martin Holdener, Selina Christen, et al.Journal of Autoimmunity|July 29, 2011
Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse modelEdith Hintermann, Martin Holdener, Monika Bayer, et al.Diabetes|February 26, 2013
Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes modelKen T Coppieters, Natalie Amirian, Philippe P Pagni, et al.Biochimica Et Biophysica Acta. Molecular Basis of Disease|June 2, 2018
Animal models of autoimmune hepatitisUrs ChristenEndocrine, Metabolic & Immune Disorders Drug Targets|March 10, 2007
Chemokines as drug targets in type 1 diabetesUrs ChristenMatrix Biology : Journal of the International Society for Matrix Biology|July 13, 2004
Epithelial cell motility on laminin-5: regulation by matrix assembly, proteolysis, integrins and erbB receptorsEdith Hintermann, Vito QuarantaClinical and Experimental Immunology|July 17, 2023
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetesUrs Christen, Laetitia Pouzol, Mélanie Tunis, et al.Pageof 10